Announcement on changing the employee representative supervisor and chairman of the board of supervisors
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders
Legal Opinion of Beijing Zhonglun Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Beijing Jiankai Technology Co., Ltd.
Jiankai Technology: 2024 Second Extraordinary General Meeting of Shareholders Meeting Information
2024 Second Extraordinary General Meeting of Shareholders Meeting Materials
Announcement on voluntary disclosure of polyethylene glycol irinotecan for the treatment of triple-negative breast cancer with brain metastasis completed the enrollment of the first patient
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Jiankai Technology: Announcement on the progress of share repurchases through centralized bidding transactions
Notice on Voluntary Disclosure of Polyethylene Glycol Irinotecan for the Treatment of Small Cell Lung Cancer Phase III Clinical Trials Completing the Enrollment of the First Case
Announcement on the Phase II Study on Voluntary Disclosure of the Safety, Tolerability and Initial Efficacy of Polyethylene Glycol Irinotecan as a Single Drug for Small Cell Lung Cancer
Announcement of reply to regulatory inquiry letter regarding information disclosure of 2023 annual report.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Beijing Jiankai Technology Co., Ltd.
2023 Annual General Meeting of Shareholders Meeting Materials
Notice on Using Idle Own Funds to Purchase Wealth Management Products
2024 Action Plan to Improve Quality, Increase Efficiency, and Value Rewards
Corporate Value and Return Promised Action Plan 2024
Announcement on the launch of foreign exchange hedging business
Notice on convening the 2023 Annual General Meeting of Shareholders
2023 Internal Control Evaluation Report
No Data
No Data